MA56504A - Dérivés de pyridin-3-yle - Google Patents
Dérivés de pyridin-3-yleInfo
- Publication number
- MA56504A MA56504A MA056504A MA56504A MA56504A MA 56504 A MA56504 A MA 56504A MA 056504 A MA056504 A MA 056504A MA 56504 A MA56504 A MA 56504A MA 56504 A MA56504 A MA 56504A
- Authority
- MA
- Morocco
- Prior art keywords
- yle
- pyridin
- derivatives
- yle derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Debugging And Monitoring (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2019065963 | 2019-06-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA56504A true MA56504A (fr) | 2022-04-27 |
Family
ID=71105482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA056504A MA56504A (fr) | 2019-06-18 | 2020-06-17 | Dérivés de pyridin-3-yle |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US12479820B2 (fr) |
| EP (1) | EP3986884A1 (fr) |
| JP (1) | JP7494222B2 (fr) |
| KR (1) | KR102786045B1 (fr) |
| CN (1) | CN114026082B (fr) |
| AR (1) | AR119162A1 (fr) |
| AU (1) | AU2020298014B2 (fr) |
| BR (1) | BR112021025236A2 (fr) |
| CA (1) | CA3143618A1 (fr) |
| CL (1) | CL2021003348A1 (fr) |
| IL (1) | IL288950B2 (fr) |
| MA (1) | MA56504A (fr) |
| MX (1) | MX2021015727A (fr) |
| PH (1) | PH12021553178A1 (fr) |
| SG (1) | SG11202111162PA (fr) |
| TW (1) | TWI845708B (fr) |
| UA (1) | UA130692C2 (fr) |
| WO (1) | WO2020254408A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3802517T (pt) | 2018-06-07 | 2023-03-20 | Idorsia Pharmaceuticals Ltd | Derivados de piridinilo substituídos por alcoxi como antagonistas do recetor de lpa1 e a sua utilização no tratamento da fibrose |
| JP7665619B2 (ja) | 2019-12-04 | 2025-04-21 | イドルシア・ファーマシューティカルズ・リミテッド | 線維性疾患の治療に使用するためのアゼチジンｌｐａ１受容体アンタゴニストのピルフェニドン及び／又はニンテダニブとの合剤 |
| WO2025169931A1 (fr) * | 2024-02-05 | 2025-08-14 | Ｕｂｅ株式会社 | Composé carboxamide |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL130088C (fr) | 1960-03-14 | |||
| WO1994006802A1 (fr) * | 1992-09-18 | 1994-03-31 | Yoshitomi Pharmaceutical Industries, Ltd. | Compose de thienodiazepine et son utilisation medicinale |
| GB9420763D0 (en) | 1994-10-14 | 1994-11-30 | Glaxo Inc | Acetamide derivatives |
| GB9919776D0 (en) | 1998-08-31 | 1999-10-27 | Zeneca Ltd | Compoujnds |
| AU7961300A (en) | 1999-10-29 | 2001-05-14 | Yamanouchi Pharmaceutical Co., Ltd. | Kainic acid neurocytotoxicity inhibitors |
| AU2001262185A1 (en) | 2000-04-10 | 2001-10-23 | Novartis Ag | Substituted (hetero)aryl carboxamide derivatives as microsomal triglyceride transfer protein (mtp) and apolipoprotein b (apo b) secretion |
| WO2002062389A1 (fr) | 2001-02-08 | 2002-08-15 | Ono Pharmaceutical Co., Ltd. | Remedes pour des maladies urinaires contenant des agents de regulation du recepteur de lpa |
| US7435824B2 (en) | 2002-04-19 | 2008-10-14 | Bristol-Myers Squibb Company | Prodrugs of potassium channel inhibitors |
| TW200403058A (en) | 2002-04-19 | 2004-03-01 | Bristol Myers Squibb Co | Heterocyclo inhibitors of potassium channel function |
| TW200505902A (en) | 2003-03-20 | 2005-02-16 | Schering Corp | Cannabinoid receptor ligands |
| WO2004110350A2 (fr) | 2003-05-14 | 2004-12-23 | Torreypines Therapeutics, Inc. | Composes et leurs utilisations pour la modulation de l'amyloide-beta |
| WO2005023761A2 (fr) | 2003-09-11 | 2005-03-17 | Kemia, Inc. | Inhibiteurs des cytokines |
| JPWO2005037269A1 (ja) | 2003-10-21 | 2006-12-28 | 住友製薬株式会社 | 新規ピペリジン誘導体 |
| EP1684759A4 (fr) | 2003-11-12 | 2009-06-10 | Merck & Co Inc | Inhibiteurs du transporteur de 4-phenyl piperidine sulfonyl glycine |
| EP1687296A1 (fr) | 2003-11-18 | 2006-08-09 | Warner-Lambert Company LLC | Derives antibacteriens d'aminoquinazolidinedione |
| WO2006091862A2 (fr) | 2005-02-24 | 2006-08-31 | Kemia, Inc. | Inhibiteurs des cytokines et utilisation therapeutique |
| CN101198590B (zh) | 2005-08-24 | 2012-05-09 | 卫材R&D管理有限公司 | 吡啶衍生物及嘧啶衍生物（3） |
| WO2007058990A2 (fr) | 2005-11-14 | 2007-05-24 | Kemia, Inc. | Therapie a base d’inhibiteurs de cytokine |
| CA2691214A1 (fr) | 2006-06-09 | 2007-12-21 | Kemia, Inc. | Therapie a base d'inhibiteurs de cytokine |
| JP5164510B2 (ja) | 2006-10-06 | 2013-03-21 | 日本曹達株式会社 | 含窒素複素環化合物および有害生物防除剤 |
| WO2008115281A2 (fr) | 2006-10-16 | 2008-09-25 | Myriad Genetics, Inc. | Composés de traitement d'infections virales |
| EP2212322B1 (fr) | 2007-10-18 | 2012-04-04 | Merck Sharp & Dohme Corp. | Modulateurs allostériques positifs du récepteur m1 de la quinolizidinone |
| AU2009239500B2 (en) | 2008-04-21 | 2014-01-30 | Lexicon Pharmaceuticals, Inc. | LIMK2 inhibitors, compositions comprising them, and methods of their use |
| PT2303270T (pt) | 2008-05-05 | 2017-08-25 | Sanofi Sa | Derivados fundidos do ácido ciclopentanocarboxílico substituídos por acilamino e sua utilização como produtos farmacêuticos |
| UY32072A (es) | 2008-08-26 | 2010-03-26 | Boehringer Ingelheim Int | Tienopirimidinas para composiciones farmacéuticas |
| KR101678255B1 (ko) * | 2009-09-25 | 2016-11-21 | 아스텔라스세이야쿠 가부시키가이샤 | 치환 아미드 화합물 |
| ES2682303T3 (es) | 2010-08-05 | 2018-09-19 | Zoetis Services Llc | Derivados de isoxazolina como agentes antiparasitarios |
| TW201305178A (zh) | 2010-10-29 | 2013-02-01 | Glenmark Pharmaceuticals Sa | 作為ｍＰＧＥＳ－１抑制物的三環化合物 |
| DK2648726T3 (da) | 2010-12-07 | 2018-07-16 | Amira Pharmaceuticals Inc | Polycyklisk lpa1-antagonist og anvendelser deraf |
| JP6097998B2 (ja) | 2010-12-16 | 2017-03-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ロイコトリエン生成のビアリールアミドインヒビター |
| PH12013501831B1 (en) | 2011-03-10 | 2019-06-14 | Zoetis Services Llc | Spirocyclic isoxazoline derivatives as antiparasitic agents |
| CA2859965A1 (fr) | 2011-12-21 | 2013-06-27 | Ardelyx, Inc. | Agonistes de tgr5 non systemiques |
| WO2014079805A1 (fr) | 2012-11-23 | 2014-05-30 | Boehringer Ingelheim International Gmbh | Composés de pyrazole pour traiter l'alopécie |
| EP2970200A1 (fr) * | 2013-03-13 | 2016-01-20 | Abbvie Inc. | Inhibiteurs de pyridine cdk9 kinase |
| ES2693718T3 (es) | 2013-11-06 | 2018-12-13 | Bristol-Myers Squibb Company | Derivados de piridina sustituidos útiles como inhibidores de GSK-3 |
| AR108185A1 (es) | 2016-04-06 | 2018-07-25 | Abbvie Inc | Amidas terciarias y método para su uso |
| PT3802517T (pt) | 2018-06-07 | 2023-03-20 | Idorsia Pharmaceuticals Ltd | Derivados de piridinilo substituídos por alcoxi como antagonistas do recetor de lpa1 e a sua utilização no tratamento da fibrose |
| JP7665619B2 (ja) | 2019-12-04 | 2025-04-21 | イドルシア・ファーマシューティカルズ・リミテッド | 線維性疾患の治療に使用するためのアゼチジンｌｐａ１受容体アンタゴニストのピルフェニドン及び／又はニンテダニブとの合剤 |
-
2020
- 2020-06-16 AR ARP200101686A patent/AR119162A1/es unknown
- 2020-06-17 WO PCT/EP2020/066767 patent/WO2020254408A1/fr not_active Ceased
- 2020-06-17 SG SG11202111162PA patent/SG11202111162PA/en unknown
- 2020-06-17 AU AU2020298014A patent/AU2020298014B2/en active Active
- 2020-06-17 EP EP20733601.7A patent/EP3986884A1/fr active Pending
- 2020-06-17 PH PH1/2021/553178A patent/PH12021553178A1/en unknown
- 2020-06-17 UA UAA202107611A patent/UA130692C2/uk unknown
- 2020-06-17 MA MA056504A patent/MA56504A/fr unknown
- 2020-06-17 TW TW109120315A patent/TWI845708B/zh active
- 2020-06-17 KR KR1020227001133A patent/KR102786045B1/ko active Active
- 2020-06-17 JP JP2021574814A patent/JP7494222B2/ja active Active
- 2020-06-17 US US17/620,520 patent/US12479820B2/en active Active
- 2020-06-17 CA CA3143618A patent/CA3143618A1/fr active Pending
- 2020-06-17 IL IL288950A patent/IL288950B2/en unknown
- 2020-06-17 MX MX2021015727A patent/MX2021015727A/es unknown
- 2020-06-17 BR BR112021025236A patent/BR112021025236A2/pt unknown
- 2020-06-17 CN CN202080044333.8A patent/CN114026082B/zh active Active
-
2021
- 2021-12-15 CL CL2021003348A patent/CL2021003348A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020254408A1 (fr) | 2020-12-24 |
| CN114026082B (zh) | 2024-06-07 |
| CA3143618A1 (fr) | 2020-12-24 |
| IL288950B1 (en) | 2024-11-01 |
| IL288950B2 (en) | 2025-03-01 |
| CN114026082A (zh) | 2022-02-08 |
| AR119162A1 (es) | 2021-12-01 |
| KR20220020921A (ko) | 2022-02-21 |
| TWI845708B (zh) | 2024-06-21 |
| MX2021015727A (es) | 2022-01-24 |
| CL2021003348A1 (es) | 2022-09-23 |
| KR102786045B1 (ko) | 2025-03-24 |
| UA130692C2 (uk) | 2026-04-22 |
| PH12021553178A1 (en) | 2022-11-07 |
| JP7494222B2 (ja) | 2024-06-03 |
| IL288950A (en) | 2022-02-01 |
| BR112021025236A2 (pt) | 2022-02-01 |
| EP3986884A1 (fr) | 2022-04-27 |
| US20220251068A1 (en) | 2022-08-11 |
| JP2022537177A (ja) | 2022-08-24 |
| AU2020298014A1 (en) | 2022-02-10 |
| US12479820B2 (en) | 2025-11-25 |
| AU2020298014B2 (en) | 2026-02-05 |
| SG11202111162PA (en) | 2021-11-29 |
| TW202115011A (zh) | 2021-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT3958977T (pt) | Derivados de camptotecina | |
| IL292753A (en) | Compounds | |
| IL292161A (en) | New methylquinazolinone derivatives | |
| EP3717479C0 (fr) | Dérivés de thiazole microbiocides | |
| EP4038058A4 (fr) | Dérivés de cannabinoïdes | |
| DK4067344T3 (da) | Cycloalkylurinstofderivat | |
| EP4013751C0 (fr) | Dérivés de 2-hydroxycycloalcane-1-carbamoyle | |
| LT3830085T (lt) | Deuterinti lanifibranoro dariniai | |
| EP3457851A4 (fr) | Dérivés de sobétirome | |
| EP4037676A4 (fr) | Dérivés cannabinoïdes | |
| EP4073033A4 (fr) | Dérivés cannabinoïdes | |
| EP3999490A4 (fr) | Dérivés cannabinoïdes | |
| EP3997095A4 (fr) | Dérivés cannabinoïdes | |
| EP4077334C0 (fr) | Dérivés furoindazole | |
| EP4021904C0 (fr) | Dérivés d'alpha-d-galactopyranoside | |
| DK3768669T3 (da) | Piperazinazaspiroderivater | |
| MA54521A (fr) | Dérivés d'oxopyridine substitués | |
| EP3885347A4 (fr) | Dérivé de dihydropyrrolopyrazole | |
| PT3796975T (pt) | Derivados de sulfonilaminobenzamida | |
| IL304774A (en) | Enhanced sophorolipid derivatives | |
| DK3823971T3 (da) | Substituerede triazol-quinoxalin-derivater | |
| EP3371163A4 (fr) | Dérivés de pyrrolidine | |
| EP4013441A4 (fr) | Formulations de larazotide | |
| MA56504A (fr) | Dérivés de pyridin-3-yle | |
| EP3472151A4 (fr) | Dérivés de prolinamide carbocycliques |